Oral Lichen Planus
Conditions
Keywords
oral lichen planus, Immune mediated condition, Topical Curcumin, Interlukin 6, ELIZA, Topical triamcinolone acetonide
Brief summary
to evaluate the therapeutic impact of curcumin as Alternative or Complementary to Triamcinolone Acetonate in Treatment of Oral Lichen Planus.
Detailed description
Background: Oral lichen planus (OLP) is a chronic inflammatory disorder affecting the mucous membranes, believed to be an immune-mediated condition. Its persisting nature can lead to extended discomfort for those affected. The primary symptoms are pain and a burning sensation, with a potential risk of malignancy if not properly managed, necessitating lifelong clinical monitoring. Presently, OLP is considered a significant challenge due to the absence of a definitive cure. Patients & patients: Thirty patients with oral lichen planus were divided into three groups, 10 patients each: Group A: ten patients with OLP were received topical triamcinolone acetonide. Group B: ten patients with OLP were received topical curcumin. Group C: ten patients with oral lichen planus were received topical triamcinolone acetonide combiend with topical curcumin. For six weeks. Each patient was examined at baseline,1 and 3months of therapy. Pain was scored using the visual analogue scale. Salivary level of interleukin 1 were estimated at baseline,1and 3 months' evaluation periods.
Interventions
DRUGtopical triamcinolone acetonide
ten patients with OLP were received topical triamcinolone acetonide four times per day for six weeks
DRUGTopical Curcumin
Ten patients with OLP received topical curcumin four times per day for six weeks.
DRUGtopical triamcinolone acetonide combiend with topical curcumin
Ten patients with OLP received a combination of topical triamcinolone acetonide and topical curcumin four times per day for six weeks.
Sponsors
Shaymaa Hussein Rafat Kotb
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
thirty patients with oral lichen planus were divided into three groups, 10 patients each: Group A: ten patients with OLP were received topical triamcinolone acetonide. Group B: ten patients with OLP were received topical curcumin. Group C: ten patients with oral lichen planus were received topical triamcinolone acetonide combiend with topical curcumin. For six weeks. Each patient was examined at baseline, 2, weeks and 1 and 3months of therapy. Pain was scored using the visual analogue scale. Salivary level of interleukin 1 were estimated at baseline, 1 and3 months' evaluation periods.
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* clinical diagnosis of OLP
Exclusion criteria
* Any systemic autoimmune disease * Any current use of anticoagulant or antiplatelet agents (curcumin has inhibitory effects on platelet aggregations). * Any topical, local or systemic corticosteroids therapy during the past 3 months. * lichenoid reaction from medications. * Pregnant or lactation women. * smokers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assess Visual Analog Scale (VAS) of OLP lesion | baseline ,1 ,3 months | Qualitative.P-value \>0.05: Non significant(NS); P-value \<0.05: Significant(S); P-value\< 0.01: highly significant(HS) |
| Assess Oral Disease Severity Score | at base line ,after 1,3 months | Qualitative.P-value \>0.05: Non significant(NS); P-value \<0.05: Significant(S); P-value\< 0.01: highly significant(HS) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Biochemical analysis of salivary interlukin 6 level using (ELISA) | baseline ,1 ,3 months | Quantity |
Countries
Egypt
Outcome results
None listed